Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000486434 | SCV000572926 | uncertain significance | not specified | 2017-02-01 | criteria provided, single submitter | clinical testing | A variant of uncertain significance has been identified in the GLI3 gene. The c.3140_3141delAGinsCA variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The c.3140_3141delAGinsCA variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The c.3140_3141delAGinsCA variant is caused by two nucleotide substitutions (c.3140 A>C and c.3141 G>A) on the same allele (in cis), resulting in an in-frame deletion of a single Glutamine residue and the insertion of a single Proline residue at amino acid position 1047, denoted Q1047P. The Q1047P variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position where amino acids with similar properties to Glutamine are tolerated across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. However, missense variants in nearby residues have not been reported in the Human Gene Mutation Database in association with GLI3-related disorders (Stenson et al., 2014). Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |
| Fulgent Genetics, |
RCV002481531 | SCV002788226 | uncertain significance | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome; Polysyndactyly 4; Polydactyly, postaxial, type A1 | 2022-05-02 | criteria provided, single submitter | clinical testing |